%0 Journal Article
%T Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of  EGFR + non-small cell lung cancer without the  T790M  mutation
%A Chenchen Zhao
%A Congjun Zhang
%A Fuxing Xiong
%A Hongyang Wu
%A Wenjun Chen
%A Xiaoqiu Li
%A Xueyang Hu
%J SCIE-indexed Journal
%D 2019
%X Lung cancer metastases to the brain are a common phenomenon. Most of them present as brain parenchymal lesions, but, simple leptomeningeal metastasis (LM) or cerebrospinal fluid (CSF) metastasis is rare (1). Brain metastasis often showed the patient had poor prognosis, but it can be improved by cranial radiotherapy and intracranial chemotherapy. However, simple LM or CSF metastasis often lack effective imaging evidence (2), some hospitals do not have the methods to test CSF, that lead the diagnosis exceedingly difficult for these patients, and lacked effective treatment method, so the prognosis became worse. In recent years, with the widespread application of comprehensive treatment for lung cancer, the survival rate of patients has gradually improved, and the probability of LM has also increased (3). More than 10% of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFR+) have been reported to show LM (4). As a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib had been shown effective in patients with T790M mutation-positive LM (5). However, there are few reports on the treatment of osimertinib in T790M negative patients with LM of lung cancer (6). We reported the clinical data of 5 patients with EGFR mutated NSCLC with LM treated in our department from January 2018 to February 2019, and analyzed the treatment process and outcome of osimertinib, to seek effective methods for the treatment of such patients
%U http://apm.amegroups.com/article/view/31811/26833